Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data

Authors: Ali Raza Khaki MD, V.K. Gadi MD, PhD and Vinay Prasad MD, MPH
View More View Less
Restricted access
  • 1.

    Ravdin PM, Siminoff LA, Davis GJ, . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980991.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Wishart GC, Azzato EM, Greenberg DC, . PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 2010;12:R1.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Sparano JA, Gray RJ, Makower DF, . Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111121.

  • 4.

    Gradishar WJ, Anderson BO, Abraham J, . NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2019. Accessed October 24, 2019. To view the most recent version, visit NCCN.org.

  • 5.

    Sparano JA, Gray RJ, Makower DF, . Prospective validation of a 21-gene expression assay in breast aancer. N Engl J Med 2015;373:20052014.

  • 6.

    Sparano JA, Gray RJ, Ravdin PM, . Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380:23952405.

  • 7.

    Cardoso F, van’t Veer LJ, Bogaerts J, . 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717729.

  • 8.

    Allison KH, Kandalaft PL, Sitlani CM, . Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 2012;131:413424.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Klein ME, Dabbs DJ, Shuai Y, . Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol 2013;26:658664.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Bhargava R, Clark BZ, Dabbs DJ. Breast cancers with Magee equation score of less than 18, or 18-25 and mitosis score of 1, do not require Oncotype DX testing: a value study. Am J Clin Pathol 2019;151:316323.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Poorvu PD, Gelber SI, Rosenberg SM, . Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 533.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Brufsky A. Deciphering genomic testing options for diverse patient populations in early-stage breast cancer. Published November 16, 2018. Available at: https://cancerletter.com/articles/20181116_4/. Accessed November 7, 2019.

  • 13.

    Blok EJ, van de Velde CJ, Smit VT. 70-Gene signature in early-stage breast cancer. N Engl J Med 2016;375:21992201.

  • 14.

    Martin M, Holmes FA, Ejlertsen B, . Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:16881700.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    von Minckwitz G, Procter M, de Azambuja E, . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377:122131.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2637 2636 182
PDF Downloads 623 623 26
EPUB Downloads 0 0 0